Teratogenic effects of antiepileptic drugs

References

• Meador KJ, Pennell PB, Harden CL et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology71(14), 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Pennell PB. EURAP outcomes for seizure control during pregnancy: useful and encouraging data. Epilepsy Curr.6(6), 186–188 (2006).
   Google Scholar
• Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology66(3), 354–360 (2006).
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D (Eds). The Blue Books of Neurology: the Epilepsies. Saunders Elsevier, PA, USA (2009).
   Google Scholar
• Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry77(2), 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res.81(1), 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Bromley RL, Baker GA, Meador KJ. Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Curr. Opin. Neurol.22(2), 162–166 (2009).
   Google Scholar
• Crombie I. Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions. Hum. Exp. Teratol.3, 261–269 (1984).
   Google Scholar
• Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res. A Clin. Mol. Teratol.85(1), 63–68 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med.344(15), 1132–1138 (2001).
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol. Clin.27(4), 993–1002 (2009).
   PubMed Web of Science ®Google Scholar
• Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol.46(5), 739–746 (1999).
   PubMed Web of Science ®Google Scholar
• Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod. Toxicol.16(1), 9–17 (2002).
   PubMed Web of Science ®Google Scholar
• Harden CL, Meador KJ, Pennell PB et al. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia50(5), 1237–1246 (2009).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Penovich P, Baker GA et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav.15(3), 339–343 (2009).
   PubMedGoogle Scholar
• Hernandez-Diaz S, Smith CR, Wyzszynski DF, Holmes LB. Risk of major malformations among infants exposed to carbamazepine during pregnancy. Birth Defects Res. A Clin. Mol. Teratol.17, 357 (2007).
   Google Scholar
• Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med.324(10), 674–677 (1991).
   PubMed Web of Science ®Google Scholar
• Thomas SV, Ajaykumar B, Sindhu K et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr. Cardiol.29(3), 604–608 (2008).
   PubMedGoogle Scholar
• Hoffman JI, Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol.39(12), 1890–1900 (2002).
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med.343(22), 1608–1614 (2000).
   PubMed Web of Science ®Google Scholar
• McLean MJ. Gabapentin. Epilepsia36(2), S73–S86 (1995).
   PubMedGoogle Scholar
• Harden CL, Pennell PB, Koppel BS et al. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia50(5), 1247–1255 (2009).
   PubMed Web of Science ®Google Scholar
• Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav.4(3), 310–317 (2003).
   PubMed Web of Science ®Google Scholar
• Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia27(5), 490–497 (1986).
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Hitchcock A, Graham J et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur. J. Neurol.13(6), 645–654 (2006).
   PubMed Web of Science ®Google Scholar
• Prakash Prabhu LV, Nasar MA, Rai R, Madhyastha S, Singh G. Lamotrigine in pregnancy: safety profile and the risk of malformations. Singapore Med. J.48(10), 880–883 (2007).
   Google Scholar
• Holmes LB, Baldwin EJ, Smith CR et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology70(22 Pt 2), 2152–2158 (2008).
   PubMed Web of Science ®Google Scholar
• Hunt SJ, Craig JJ, Morrow JI. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology72(12), 1108; author reply 1108–1109 (2009).
   Google Scholar
• Holmes LB, Smith CR, Hernandez-Diaz S. Pregnancy registries; larger samples sizes essential. Birth Defects Res. A Clin. Mol. Teratol.82, 307 (2008).
   Google Scholar
• Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch. Neurol.61(5), 673–678 (2004).
   PubMed Web of Science ®Google Scholar
• Loughnan PM, Gold H, Vance JC. Phenytoin teratogenicity in man. Lancet1(7794), 70–72 (1973).
   Google Scholar
• Hanson JW, Smith DW. The fetal hydantoin syndrome. J. Pediatr.87(2), 285–290 (1975).
   PubMed Web of Science ®Google Scholar
• Hanson JW, Smith DW. Fetal hydantoin syndrome. Lancet1(7961), 692 (1976).
   Google Scholar
• Hanson JW. Teratogen update: fetal hydantoin effects. Teratology33(3), 349–353 (1986).
   Google Scholar
• Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res.33(2–3), 145–158 (1999).
   PubMed Web of Science ®Google Scholar
• Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr.93(2), 174–176 (2004).
   PubMed Web of Science ®Google Scholar
• Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology64(11), 1874–1878 (2005).
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Hitchcock A, Graham J, O’Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust. NZ J. Obstet. Gynaecol.47(6), 468–474 (2007).
   PubMed Web of Science ®Google Scholar
• Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res.87(2–3), 124–129 (2009).
   PubMedGoogle Scholar
• Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod. Toxicol.25(3), 388–389 (2008).
   PubMed Web of Science ®Google Scholar
• Hunt S, Russell A, Smithson WH et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology71(4), 272–276 (2008).
   PubMed Web of Science ®Google Scholar
• Fountain NB. A pregnant pause to consider teratogenicity of topiramate. Epilepsy Curr.9(2), 36–38 (2009).
   Google Scholar
• Artama M, Ritvanen A, Gissler M, Isojarvi J, Auvinen A. Congenital structural anomalies in offspring of women with epilepsy – a population-based cohort study in Finland. Int. J. Epidemiol.35(2), 280–287 (2006).
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol. Scand.112(3), 137–143 (2005).
   PubMed Web of Science ®Google Scholar
• Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology64(6), 955–960 (2005).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Finnell RH et al.In utero antiepileptic drug exposure: fetal death and malformations. Neurology67(3), 407–412 (2006).
   PubMed Web of Science ®Google Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br. Med. J.314(7075), 180–181 (1997).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Evaluation of Medicines for Human Use, Opinion of the Committee for Proprietary Medicinal Products pursuant to Article 12 of Council Directive 75/319/EEC as Amended for Vigabatrin. CPMP/1357/99-ENCPMP/1357/99-EN. EMEA, London, UK (1999).
   Google Scholar
• Sorri I, Herrgard E, Viinikainen K, Paakkonen A, Heinonen S, Kalviainen R. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. Epilepsy Res.65(1–2), 117–120 (2005).
   PubMed Web of Science ®Google Scholar
• Lawthom C, Smith PE, Wild JM. In utero exposure to vigabatrin: no indication of visual field loss. Epilepsia50(2), 318–321 (2009).
   PubMed Web of Science ®Google Scholar
• Adams DF, Ment LR, Vohr B. Antenatal therapies and the developing brain. Semin. Neonatol.6(2), 173–183 (2001).
   Google Scholar
• Vorhees CV. Fetal anticonvulsant exposure: effects on behavioral and physical development. Ann. NY Acad. Sci.477, 49–62 (1986).
   Google Scholar
• Thomas SV, Ajaykumar B, Sindhu K, Nair MK, George B, Sarma PS. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav.13(1), 229–236 (2008).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med.360(16), 1597–1605 (2009).
   PubMed Web of Science ®Google Scholar
• McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav.16(4), 609–616 (2009).
   PubMed Web of Science ®Google Scholar
• Kantola-Sorsa E, Gaily E, Isoaho M, Korkman M. Neuropsychological outcomes in children of mothers with epilepsy. J. Int. Neuropsychol. Soc.13(4), 642–652 (2007).
   PubMed Web of Science ®Google Scholar
• Titze K, Koch S, Helge H, Lehmkuhl U, Rauh H, Steinhausen HC. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev. Med. Child. Neurol.50(2), 117–122 (2008).
   PubMed Web of Science ®Google Scholar
• Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia37(12), 1242–1244 (1996).
   PubMed Web of Science ®Google Scholar
• Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology60(4), 575–579 (2003).
   PubMed Web of Science ®Google Scholar
• Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia44(Suppl. 3), 33–40 (2003).
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur. J. Epidemiol.8(1), 122–127 (1992).
   Google Scholar
• Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr. Med. Res. Opin.21(5), 693–701 (2005).
   PubMed Web of Science ®Google Scholar
• Safra MJ, Oakley GP Jr. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet2(7933), 478–480 (1975).
   PubMed Web of Science ®Google Scholar
• Safra MJ, Oakley GP Jr. Valium: an oral cleft teratogen? Cleft Palate J.13, 198–200 (1976).
   PubMedGoogle Scholar
• Rosenberg L, Mitchell AA, Parsells JL, Pashayan H, Louik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. N. Engl. J. Med.309(21), 1282–1285 (1983).
   PubMed Web of Science ®Google Scholar
• Gidai J, Acs N, Banhidy F, Czeizel AE. No association found between use of very large doses of diazepam by 112 pregnant women for a suicide attempt and congenital abnormalities in their offspring. Toxicol. Ind. Health24(1–2), 29–39 (2008).
   PubMed Web of Science ®Google Scholar
• Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol. Drug Saf.16(11), 1203–1210 (2007).
   PubMed Web of Science ®Google Scholar
• Harden CL, Hopp J, Ting TY et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology73(2), 126–132 (2009).
   PubMed Web of Science ®Google Scholar
• Harden CL, Meador KJ, Pennell PB et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology73(2), 133–141 (2009).
   PubMed Web of Science ®Google Scholar
• Harden CL, Pennell PB, Koppel BS et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology73(2), 142–149 (2009).
   PubMed Web of Science ®Google Scholar
• Fritz H, Muller D, Hess R. Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. Toxicology6(3), 323–330 (1976).
   PubMed Web of Science ®Google Scholar
• Sullivan FM, McElhatton PR. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol. Appl. Pharmacol.40(2), 365–378 (1977).
   PubMed Web of Science ®Google Scholar
• Paulson RB, Paulson GW, Jreissaty S. Phenytoin and carbamazepine in production of cleft palates in mice. Comparison of teratogenic effects. Arch. Neurol.36(13), 832–836 (1979).
   Google Scholar
• Eluma FO, Sucheston ME, Hayes TG, Paulson RB. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus. J. Craniofac. Genet. Dev. Biol.4(3), 191–210 (1984).
   PubMedGoogle Scholar
• Eluma FO, Sucheston ME, Hayes TG, Paulson RB. The teratogenic effects of carbamazepine in the CD-I mouse fetus. Teratology23, A33 (1981).
   Google Scholar
• Finnell RH, Mohl VK, Bennett GD, Taylor SM. Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratog. Carcinog. Mutagen6(5), 393–401 (1986).
   Google Scholar
• El-Sayed MG, Aly AE, Kadri M, Moustafa AM. Comparative study on the teratogenicity of some antiepileptics in the rat. East Afr. Med. J.60(6), 407–415 (1983).
   Google Scholar
• Vorhees CV. Fetal anticonvulsant syndrome in rats: dose– and period–response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. J. Pharmacol. Exp. Ther.227(2), 274–287 (1983).
   Google Scholar
• Finnell RH, Bennett GD, Slattery JT, Amore BM, Bajpai M, Levy RH. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology52(6), 324–332 (1995).
   PubMedGoogle Scholar
• Lindhout D, Hoppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia25(1), 77–83 (1984).
   PubMed Web of Science ®Google Scholar
• Bennett GD, Amore BM, Finnell RH et al. Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse. J. Pharmacol. Exp. Ther.279(3), 1237–1242 (1996).
   PubMed Web of Science ®Google Scholar
• Tecoma ES. Oxcarbazepine. Epilepsia40(Suppl. 5), S37–S46 (1999).
   PubMedGoogle Scholar
• Prakash Prabhu LV, Rai R et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singapore Med. J.49(1), 47–53 (2008).
   Google Scholar
• Manent JB, Jorquera I, Franco V, Ben-Ari Y, Perucca E, Represa A. Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res.78(2–3), 131–139 (2008).
   PubMed Web of Science ®Google Scholar
• Bastaki SM, Padmanabhan R, Abdulrazzaq YM, Chandranath SI, Shafiulla M. Studies on the teratogenic effects of lamotrigine in mouse fetuses. Front. Fetal Health3(11–12), 295 (2001).
   Google Scholar
• Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah M, Chandranath SI. Experimental studies on reproductive toxicologic effects of lamotrigine in mice. Birth Defects Res. B Dev. Reprod. Toxicol.68(5), 428–438 (2003).
   Google Scholar
• Prakash Prabhu LV, Singh G. Effects of folate supplementation on cleft palate induced by lamotrigine or cyclophosphamide: an experimental study in mice. Neuroanatomy6, 12–16 (2007).
   Google Scholar
• Isoherranen N, Spiegelstein O, Bialer M et al. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-α-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia44(10), 1280–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Drug Information for the Health Care Professional (Volume 1). Thomson/Micromedex, CO, USA 1816 (2007).
   Google Scholar
• Finnell RH, Shields HE, Taylor SM, Chernoff GF. Strain differences in phenobarbital-induced teratogenesis in mice. Teratology35(2), 177–185 (1987).
   PubMedGoogle Scholar
• Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J.281(Pt 3), 577–592 (1992).
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Dudley CN, Cunningham ML. Biochemical effects of the mouse hepatocarcinogen oxazepam: similarities to phenobarbital. Fundam. Appl. Toxicol.29(1), 147–154 (1996).
   PubMedGoogle Scholar
• Massey KM. Teratogenic effects of diphenylhydantoin sodium. J. Oral Ther. Pharmacol.2(5), 380–385 (1966).
   PubMedGoogle Scholar
• Harbison RD, Becker BA. Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice. Teratology2(4), 305–311 (1969).
   PubMedGoogle Scholar
• Mercier-Parot L, Tuchmann-Duplessis H. The dysmorphogenic potential of phenytoin: experimental observations. Drugs8(5), 340–353 (1974).
   Google Scholar
• Harbison RD, Becker BA. Diphenylhydantoin teratogenicity in rats. Toxicol. Appl. Pharmacol.22(2), 193–200 (1972).
   PubMed Web of Science ®Google Scholar
• Khera KS. A teratogenicity study on hydroxyurea and diphenylhydantoin in cats. Teratology20(3), 447–452 (1979).
   PubMedGoogle Scholar
• McClain RM, Langhoff L. Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology21(3), 371–379 (1980).
   PubMedGoogle Scholar
• Sulik KK, Johnston MC, Ambrose LJ, Dorgan D. Phenytoin (dilantin)-induced cleft lip and palate in A/J mice: a scanning and transmission electron microscopic study. Anat. Rec.195(2), 243–255 (1979).
   PubMedGoogle Scholar
• Elshove J. Ceft palate in the offspring of female mice treated with phenytoin. Lancet2(7629), 1074 (1969).
   Google Scholar
• Abela D, Howe AM, Oakes DA, Webster WS. Maternal antioxidant supplementation does not reduce the incidence of phenytoin-induced cleft lip and related malformations in rats. Birth Def. Res. B Dev. Reprod. Toxicol.74(2), 201–206 (2005).
   Google Scholar
• Finnell RH, Chernoff GF. Variable patterns of malformation in the mouse fetal hydantoin syndrome. Am. J. Med. Genet.19(3), 463–471 (1984).
   Google Scholar
• McDevitt JM, Gautieri RF, Mann DE Jr. Comparative teratogenicity of cortisone and phenytoin in mice. J. Pharm. Sci.70(6), 631–634 (1981).
   Google Scholar
• Finnell RH, van Waes M, Musselman A, Kerr BM, Levy RH. Differences in the patterns of phenytoin-induced malformations following stiripentol coadministration in three inbred mouse strains. Reprod. Toxicol.7(5), 439–448 (1993).
   Google Scholar
• Finnell RH. Phenytoin-induced teratogenesis: a mouse model. Science211(4481), 483–484 (1981).
   PubMed Web of Science ®Google Scholar
• Martz F, Failinger C 3rd, Blake DA. Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J. Pharmacol. Exp. Ther.203(1), 231–239 (1977).
   PubMed Web of Science ®Google Scholar
• Wells PG, Harbison RD. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their roles in phenytoin-induced teratology. In: Phenytoin-Induced Teratology and Gingival Pathology. Hassell TM, Johnston MC, Dudley KH (Eds). Raven Press, NY, USA 83–108 (1980).
   Google Scholar
• Lum JT, Wells PG. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology33(1), 53–72 (1986).
   PubMedGoogle Scholar
• Chang T, Savory A, Glazko AJ. A new metabolite of 5,5-diphenylhydantoin (Dilantin). Biochem. Biophys. Res. Commun.38(3), 444–449 (1970).
   PubMed Web of Science ®Google Scholar
• Jerina DM, Daly JW. Arene oxides: a new aspect of drug metabolism. Science185(151), 573–582 (1974).
   PubMed Web of Science ®Google Scholar
• Strickler SM, Dansky LV, Miller MA, Seni MH, Andermann E, Spielberg SP. Genetic predisposition to phenytoin-induced birth defects. Lancet2(8458), 746–749 (1985).
   PubMed Web of Science ®Google Scholar
• Blake DA, Martz F. Covalent binding of phenytoin metabolites in fetal tissue. In: Phenytoin-Induced Teratology and Gingival Pathology. Hassell TM, Johnston M, Dudley KH (Eds). Raven Press, NY, USA 75–80 (1980).
   Google Scholar
• Pantarotto C, Arboix M, Sezzano P, Abbruzzi R. Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem. Pharmacol.31(8), 1501–1507 (1982).
   PubMed Web of Science ®Google Scholar
• Wells PG, Vo HP. Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice. Toxicol. Appl. Pharmacol.97(3), 398–405 (1989).
   PubMed Web of Science ®Google Scholar
• Kubow S, Wells PG. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol. Pharmacol.35(4), 504–511 (1989).
   PubMed Web of Science ®Google Scholar
• Winn LM, Wells PG. Evidence for Ras-dependent signal transduction in phenytoin teratogenicity. Toxicol. Appl. Pharmacol.184(3), 144–152 (2002).
   Google Scholar
• Diepold C, Eyer P, Kampffmeyer H, Reinhardt K. Reactions of aromatic compounds with thiols. In: Biological Reactive Intermediates: 2: Chemical Mechanisms and Biological Effects, Volume B. Snyder R, Parke DV, Kocsis JJ, Jollow DJ, Gibson CG, Witmer CM (Eds). Plenum Press, NY, USA (1982).
   Google Scholar
• Moldeus P, Jemstrom B. Interaction of glutathione with reactive intermediates. In: Functions of Glutathione: Biochemical, Physiological, Toxicological and Clinical Aspects. Larsson A, Orrenius S, Holmgren A, Mannervik B (Eds). Raven Press, NY, USA 99–108 (1983).
   Google Scholar
• Harbison RD. Chemical-biological reactions common to teratogenesis and mutagenesis. Environ. Health Perspect.24, 87–100 (1978).
   PubMedGoogle Scholar
• Winn LM, Wells PG. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol.48(1), 112–120 (1995).
   PubMed Web of Science ®Google Scholar
• Finnell RH, Bennett GD, Mather GG, Wlodarczyk B, Bajpai M, Levy RH. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod. Toxicol.13(2), 85–91 (1999).
   PubMed Web of Science ®Google Scholar
• Finnell RH, Kerr BM, van Waes M, Steward RL, Levy RH. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia35(1), 141–148 (1994).
   PubMed Web of Science ®Google Scholar
• Drug Information for the Health Care Professional. Thomson/Micromedex, CO, USA 2785 (2007).
   Google Scholar
• Nau H, Hendrickx G. Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol.1, 52–56 (1987).
   Google Scholar
• Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J.19(9), 1166–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Petrere JA, Anderson JA, Sakowski R, Fitzgerald JE, de la Iglesia FA. Teratogenesis of calcium valproate in rabbits. Teratology34(3), 263–269 (1986).
   PubMedGoogle Scholar
• Hendrickx AG, Nau H, Binkerd P et al. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology38(4), 329–345 (1988).
   Google Scholar
• Finnell RH, Bennett GD, Karras SB, Mohl VK. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology38(4), 313–320 (1988).
   PubMedGoogle Scholar
• Ehlers K, Sturje H, Merker HJ, Nau H. Valproic acid-induced spina bifida: a mouse model. Teratology45(2), 145–154 (1992).
   PubMedGoogle Scholar
• Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog. Carcinog. Mutagen16(2), 97–108 (1996).
   PubMedGoogle Scholar
• Emmanouil-Nikoloussi EN, Foroglou NG, Kerameos-Foroglou CH, Thliveris JA. Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie88(280), 41–45 (2004).
   PubMedGoogle Scholar
• Nau H. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol. Appl. Pharmacol.80(2), 243–250 (1985).
   PubMed Web of Science ®Google Scholar
• Niedermeyer E. Epilepsy Guide: Diagnosis and Treatment of Epileptic Seizure Disorders. Urban & Schwarzenberg, Munich, Germany (1983).
   Google Scholar
• Finnell RH, Moon SP, Abbott LC, Golden JA, Chernoff GF. Strain differences in heat-induced neural tube defects in mice. Teratology33(2), 247–252 (1986).
   PubMedGoogle Scholar
• Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH. Valproic acid-induced alterations in growth and neurotrophic factor gene expression in murine embryos. Reprod. Toxicol.14(1), 1–11 (2000).
   PubMed Web of Science ®Google Scholar
• Nau H, Loscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam. Appl. Toxicol.6(4), 669–676 (1986).
   PubMedGoogle Scholar
• Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J. Control. Release62(1–2), 187–192 (1999).
   Google Scholar
• Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology42(4 Suppl. 5), 17–24 (1992).
   PubMedGoogle Scholar
• Alonso-Aperte E, Ubeda N, Achon M, Perez-Miguelsanz J, Varela-Moreiras G. Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation. Neurology52(4), 750–756 (1999).
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem.276(39), 36734–36741 (2001).
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J.20(24), 6969–6978 (2001).
   PubMed Web of Science ®Google Scholar
• Menegola E, Di Renzo F, Broccia ML et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Def. Res. B Dev Reprod. Toxicol.74(5), 392–398 (2005).
   PubMed Web of Science ®Google Scholar
• Eikel D, Lampen A, Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol.19(2), 272–278 (2006).
   PubMed Web of Science ®Google Scholar
• Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of β-catenin – developmental effects of valproic acid. Crit. Rev. Toxicol.35(8–9), 727–738 (2005).
   PubMed Web of Science ®Google Scholar
• Abdulrazzaq YM, Bastaki SM, Padmanabhan R. Teratogenic effects of vigabatrin in TO mouse fetuses. Teratology55(3), 165–176 (1997).
   PubMedGoogle Scholar
• Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah MM. Intrauterine growth restriction and skeletal variations in mouse fetuses induced by vigabatrin administered at preimplantation stages of development. Congenit. Anom. (Kyoto)48(1), 29–39 (2008).
   Google Scholar
• Manent JB, Jorquera I, Mazzucchelli I et al. Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia48(4), 684–693 (2007).
   PubMed Web of Science ®Google Scholar
• Long L. Levetiracetam monotherapy during pregnancy – a case series. Epilepsy Behav.4(4), 447–448 (2003).
   PubMed Web of Science ®Google Scholar
• ten Berg K, Samrén B, van Oppen C, Martijn E, Lindhoudt D. Levetiracetam use and pregnancy outcome. Reprod. Toxicol.20(1), 175–178 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt S, Craig J, Russell A et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology67(10), 1876–1879 (2006).
   PubMed Web of Science ®Google Scholar
• Pitkin RM. Folate and neural tube defects. Am. J. Clin. Nutr.85(1), S285–S288 (2007).
   PubMed Web of Science ®Google Scholar
• Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm. Rep.41(RR-14), 1–7 (1992).
   PubMedGoogle Scholar
• Van Allen MI, Fraser FC, Dallaire L et al. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Clinical Teratology Committee, Canadian College of Medical Geneticists. CMAJ149(9), 1239–1243 (1993).
   Google Scholar
• Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur. J. Obstet. Gynecol. Reprod. Biol.78(2), 151–161 (1998).
   PubMed Web of Science ®Google Scholar
• Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure8(4), 253–254 (1999).
   PubMed Web of Science ®Google Scholar
• Candito M, Naimi M, Boisson C et al. Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. Birth Def. Res. A Clin. Mol. Teratol.79(1), 62–64 (2007).
   PubMed Web of Science ®Google Scholar
• Pittschieler S, Brezinka C, Jahn B et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J. Neurol.255(12), 1926–1931 (2008).
   PubMed Web of Science ®Google Scholar
• Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod. Toxicol.28(1), 1–10 (2009).
   PubMed Web of Science ®Google Scholar
• Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology61(6 Suppl. 2), S23–S26 (2003).
   PubMed Web of Science ®Google Scholar
• Nambisan M, Wyszynski DF, Holmes LB. No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Def. Res. A Clin. Mol. Teratol.6(5), 364 (2003).
   Google Scholar
• Morrell MJ. Guidelines for the care of women with epilepsy. Neurology51(5 Suppl. 4), S21–S27 (1998).
   Web of Science ®Google Scholar
• Morrow JI, Hunt SJ, Russell AJ et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry80(5), 506–511 (2009).
   PubMed Web of Science ®Google Scholar
• Kjaer D, Horvath-Puho E, Christensen J et al. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case–control study. BJOG115(1), 98–103 (2008).
   PubMedGoogle Scholar